The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...

GoodRx has named 20 medications and vaccines as the most influential FDA approvals of 2025, spotlighting first-in-class drugs, new indications, and therapies with the potential to significantly affect ...

Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...

Pharmaceutical companies in the U.S. plan to increase prices on 350 medications despite political pressure. Vanda ...

The reason you might feel nauseous when moving is because your brain is getting conflicting information from various parts ...

Bengaluru: Vanda Pharmaceuticals said on Tuesday ‍its drug for the prevention of motion-induced vomiting was approved by the ...

Vanda Pharmaceuticals received FDA approval for Nereus for motion sickness, and its shares offer upside potential into 2026 ...